Affordable Access

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.

Authors
Type
Published Article
Journal
Circulation
Publication Date
Volume
97
Issue
4
Pages
340–349
Identifiers
PMID: 9468207
Source
Medline
License
Unknown

Abstract

The oral glycoprotein IIb/IIIa antagonist sibrafiban achieved effective, long-term platelet inhibition with a clear dose-response but at the expense of a relatively high incidence of minor bleeding. Oral IIb/IIIa inhibition deserves further study as a new treatment strategy in patients after acute coronary syndromes.

Statistics

Seen <100 times